MedTrace Logo

A Study to Investigate 14C-bemcentinib in Healthy Male Subjects

NCT06469138 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-01-29

Study results available
· View outcomes & findings →

Summary

The aims of this Study were to determine:

* How much of the Study Drug (bemcentinib) ends up in urine and faeces
* How much of the Study Drug and its breakdown products get into the bloodstream
* The breakdown products (metabolites) of the Study Drug
* The safety of the Study Drug and any side effects that might be associated with it.

Conditions

Interventions

DRUG

Bemcentinib

Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.

Sponsors & Collaborators

  • BerGenBio ASA

    lead INDUSTRY

Principal Investigators

  • Dr Brooks, MBChB · Labcorp Clinical Research Unit Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-02
Primary Completion
2022-09-23
Completion
2022-09-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06469138 on ClinicalTrials.gov